Sorry, the video which you have requested is not yet processed.

Filter By:
http://cance... Immunotherapy Forum Video #3: In Part 1 of 2 videos on this topic, Dr. Matthew Hellmann from the Memorial Sloan Kettering Cancer Center discusses the century-long history of attempting to treat cancer with immunotherapy. GRACEcast 295 CA Rx
by:cancergrace | 4 views
A molecular-based approach in MPN studies, which has improved understanding of driver mutations, has rapidly increased recent advances in clinical management. Combinational therapies are in preliminary stages and focus is on the Janus kinase (JAK) inhibitor, ruxolitinib, in combinations that enhance...
by:EMJ | 18 views
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Denis-Claude Roy (University of Montreal, Montreal, Canada) discusses a phase II trial that evaluated selective photodepletion of recipient-allor​eactive T-cells (ATIR) for haploidentical haematopoietic stem cell transplant in patien...
by:EMJ | 34 views
During the 2014 American Society of Hematology (ASH) annual meeting, Dr. Ruben Mesa from Mayo Clinic Arizona joined Patient Power to discuss the recent FDA approval of ruxolitinib (Jakafi®) for the treatment of polycythemia vera (PV)—the first medicine approved specifically to treat PV. Dr. Mesa exp...
by:patientpower | 33 views
During the 2014 American Society of Hematology (ASH) annual meeting, Dr. Ajay Gopal from Seattle Cancer Care Alliance joined Patient Power to share exciting treatment news for lymphomas. He provided an overview of all the latest, including positive news about the oral therapy Zydelig® (idelalisib) i...
by:patientpower | 18 views
As part of our coverage of the 2014 American Society of Hematology (ASH) annual meeting, Dr. Srdan Verstovsek from MD Anderson Cancer Center led a Patient Power roundtable discussion featuring Dr. Ross Levine from Memorial Sloan Kettering Cancer Center and Dr. Francesco Passamonti from Ospedale di C...
by:patientpower | 6 views
Renowned expert Dr. Michael Keating, whose devotion to CLL patients that spans decades, looks at the past and future of CLL research and treatment. Joined by Andrew Schorr, by his patient, and Patient Power founder, Dr. Keating explores how far CLL research has come, and where it may be headed. Dr. ...
by:patientpower | 6 views
In the past few years, there has been an explosion of new data on efficacious targeted and immunotherapeut​ic approaches for the management of malignant melanoma. Multiple treatment options currently exist with potential for clinical benefit and improvement in outcomes for melanoma patients, creating the need to fully comprehend the advantages and d...
by:imedex | 20 views
Advances in our understanding of the molecular and genetic mechanisms underlying the pathogenesis of lung cancer have led to a dramatic expansion in the multidisciplina​ry approaches to the management of thoracic malignancies in the past decade with a growing number of new and improved targeted agents and efficacious combination regimens. With the a...
by:imedex | 16 views
In recent years, the focus of NSCLC treatment has shifted to identifying and targeting specific tumor mutations, leading to individualized therapy. Targeting the epidermal growth factor receptor (EGFR) has played a central role in advancing NSCLC research, treatment, and patient outcomes over the last several years. Despite an initial benefit from ...
by:imedex | 18 views
Please help us provide the best service.
I'm intersted in oncology videos because I'm a...

Different type of MD 
Other oncology Professional 
Something Else 

No Thanks(close window)
Membership has its privileges.
 I want the OncologyTube newsletter 

 I want to share videos & receive the newsletter 

I already have an account log me in.

username:   password: remember me

Sign In

Remember me
Forgot your password?
Not Yet a Member? Sign up for FREE here!
(Skip Ad)